Clinicopathological categorization of hydroa vacciniforme-like lymphoproliferative disorder: an analysis of prognostic implications and treatment based on 19 cases

Guo Na1,2†, Chen Yueqiong1,3†, Wang Yu1,4, Huang Yuhua1,2, Feng Yanfen1,2, Li Min1,2 and Rao Huilan1,2*

Abstract

Background: Hydroa vacciniforme-like lymphoproliferative disorder (HV-LPD) is a cutaneous form of chronic active Epstein-Barr virus (EBV) infection, which occurs mainly in children in Latin America and Asia. It can progress to systemic lymphoma. However, prognostic factors and treatment remain unclear.

Methods: This retrospective study reviewed the clinical, morphologic, immunophenotypical features, and clinical treatment of 19 patients with HV-LPD.

Results: All 19 patients had skin lesions in the face, extremities, or areas unexposed to the sun, including edema, blistering, ulceration, and scarring. The course was slowly progressive and relapsing. Histopathology showed an atypical lymphocytic infiltrate in the dermis and/or subcutaneous tissue. The lesions had a cytotoxic T/NK-cell immunophenotype. Among 19 patients, 7 (37%) exhibited CD4+ T cells, 5 (26%) exhibited CD8+ T cells, and 7 (37%) exhibited CD56+ cells. Of 12 cases with a T-cell phenotype, molecular analyses demonstrated that 7 had monoclonal rearrangements in the T-cell receptor genes. Three cases had an NK-cell phenotype and had polyclonal rearrangements in the TCR genes. All cases were associated with EBV infections. Among 19 patients, 9 (47.4%) received chemotherapy. Only one patient received allogeneic transplantation and EBV-specific cytotoxic T lymphocyte treatment after chemotherapy. That patient was the only one alive without disease at the latest follow up. Nine patients died of systemic lymphoma with disease progression, indicating irreversible process.

Conclusions: This study confirmed that HV-LPD is a broad-spectrum EBV+ lymphoproliferative disorder. It progressed to EBV+ systemic T/NK lymphoma, although some patients had a more indolent, chronic course. Cytopenia, elevated lactate dehydrogenase, destructive-multiorgan involvement, and older age were poor prognostic factors. Only allogeneic transplantation was curative.

Keywords: Epstein-Barr virus-positive, Hydroa vacciniforme-like lymphoproliferative disorder, Clinicopathologic features, Prognostic factors, Treatment
Introduction
Hydroa vacciniforme-like lymphoproliferative disorder (HV-LPD) was nominated and introduced into the 4th revised edition of the WHO classification of Tumors of Hematopoietic and Lymphoid Tissues [1]. HV-LPD is a cutaneous form of Epstein-Barr Virus-positive (EBV+) T/NK lymphoproliferative disease, which occurs in childhood and carries the risk of systemic lymphoma [2, 3]. Other terms have been used previously to describe HV-LPD, including hydroa vacciniforme-like eruption, edematous scarring vasculitic panniculitis, classic and severe hydroa vacciniforme, hydroa-like cutaneous T-cell lymphoma, and hydroa vacciniforme-like lymphoma (HVLL) [3]. The term HVLL was included the 2008 WHO classification of peripheral mature T-cell lymphoma [4]. The nomenclature and definition changed from HVLL to lymphoproliferative disorder, due to its relationship with chronic active EBV (CAEBV) infections and its clinical course.

HV-LPD is extremely rare. It manifests as recurrent skin lesions infiltrated with T cells or NK cells. It is mostly found in children and young adults from Asian and Latin American countries. It is associated with CAEBV infections. It might persist only in genetically predisposed individuals [5–7].

The clinical course of HV-LPD is variable; it lasts up to 10–15 years [8, 9]. In the early stage, skin lesions tend to occur on sun-exposed areas. Lesions comprise recurrent papulovesicles, crusts, and eventually, vacciniform (pox-like) scars, after several weeks. In the late stage, this disorder involves areas unexposed to the sun and becomes more aggressive. Deep ulcerations, necrosis, and facial edema are common. Severe systemic manifestations might be present, such as intermittent fever, lymph node enlargement, and hepatosplenomegaly. When systemic dissemination occurs (hepatosplenomegaly, lymphadenopathy, and bone marrow infiltration), it is best classified as systemic EBV+ T/NK-cell lymphoma [2, 3].

However, it is not always possible to distinguish between HV-LPD and systemic EBV+ T/NK-cell lymphoma, because these disorders often have overlapping clinical and pathological features at the time of presentation and/or during disease progression [10, 11]. Moreover, patients with HV-LPD exhibit variable clinical courses, but often have fatal outcomes. There are no guidelines or consensus opinions to guide clinicians in making a HV-LPD diagnosis, evaluating disease progression, or selecting treatment. Therefore, we retrospectively reviewed 19 cases of HV-LPD, first to characterize further the clinicopathological and molecular features, and second, to propose clinicopathological prognostic factors and potentially effective treatment.

Materials and methods
Patient selection
All patients were examined at the Department of Pathology, Sun Yat-sen University Cancer Center, from September 2008 to May 2017. The HV-LPD diagnosis was based on the 4th revised edition of the WHO classification of Tumors of Hematopoietic and Lymphoid Tissues [1]. The HV-LPD diagnosis was also based on standard published clinical and histopathological criteria, immunohistochemistry results, and findings of T-cell receptor (TCR) rearrangements. Tissue specimens were fixed in neutral buffered formalin and embedded in paraffin for processing. Hematoxylin-eosin stained sections, immunohistochemical staining, in situ hybridization for detecting EBV-encoded RNAs (EBERs), and molecular studies were performed at the Department of Pathology.

Patient follow-up
Of the 19 patients identified, 9 patients had at least one treatment record in the Sun Yat-sen University Cancer Center. Another five patients were treated at other hospitals. Clinical data and follow-up information were obtained from the hospital and from private medical office records. All patients were followed up until May 2017. Disease progression and recurrence were diagnosed based on clinical examinations, imaging assessments, and pathologic examinations. Overall survival (OS) was measured from the initiation of treatment to either the last follow-up or death from disease. Progression-free survival (PFS) was measured from the initiation of treatment to the first indications of disease progression or relapse, death from disease, or the last follow-up.

Hematoxylin-eosin staining
HV-LPD tissues were formalin-fixed, paraffin-embedded, and stained with hematoxylin and eosin. The histopathological features of the 19 cases were evaluated independently by two pathologists (Y-H H and H-L R).

Immunohistochemical staining and EBV in situ hybridization
The tissue blocks were cut into 4-μm sections and processed for immunohistochemistry. The lineage of EBV+ cells was determined by staining with antibodies against CD3, CD5, CD4, CD8, CD56, CD30, TIA1, and Ki67. Immunohistochemical stains were performed with an automated immunostainer (Ventana Medical Systems, Tucson, AZ), according to the manufacturer’s protocol. EBV was detected with the EBV Probe In Situ Hybridization Kit (TRIPLEX INTERNATIONAL BIOSCIENCES, CHINA, CO. LTD).

T-cell clonality studies
Polymerase chain reaction (PCR) was performed to analyze the clonality of T cells. We use the standardized BIOMED-2 clonality assays-ABI Fluorescence Detection (Identiclone, In Vivo Scribe Technologies, San Diego, CA, USA) according to the manufacturer’s instructions. PCR
products were analysed by capillary electrophoresis using an ABI 3500XL genetic analyser (Applied Biosystems, Foster City, CA, USA). DNA quality was assessed through amplification of a control gene size ladder.

First, after deparaffinization and proteinase K digestion, DNA was extracted from 10-mm paraffin sections, according to the standard procedure. Then, T-cell clonal expansion was detected by analyzing rearrangements in the TCR beta chain (Vb-Jb and Db-J-b) and TCR genes. Positive and negative controls were set appropriately in all experiments. Clonality was assessed according to well-established recommendations.

**EBV DNA blood load measurement**

Total plasma cell-free DNA was isolated with the QIAamp Blood Mini Kit (QIAGen, Inc., Valencia, CA, USA), according to the manufacturer's protocol. Plasma levels of EBV DNA toward the BamHI-W region were determined with the quantitative PCR method. The primers were designed as previously reported [12]. DNA from EBV-negative healthy volunteers comprised one negative control, and another negative control was run with no template. Controls were included on each plate. Results are expressed as the number of EBV copies/ml plasma. Zero copies/ml was selected for the cut-off value in evaluating EBV DNA levels.

There was a positive control used for EBV DNA detection each time. To estimate the sensitivity of the PCR assay, gradient dilutions of the synthetic EBV fragment plasmid were prepared and amplified by the PCR assay. Using absolute quantification, a standard curve was made by 10^3, 10^4, 10^5 and 10^6. And 10^3 and 10^5 were used as positive controls.

**Statistical analysis**

Data are described as the mean ± standard deviation (SD), range, frequency (number of cases), and percentages, when appropriate. All statistical calculations were performed with the Statistical Package for Social Sciences software, version 20 (SPSS, Inc. Chicago, IL, USA).

**Results**

**Clinical characteristics**

Nineteen cases were diagnosed in our center from September 2008 to May 2017. The incidence of HV-LPD was 1.9% among patients with mature peripheral T-cell lymphoma in our center [13]. The cohort comprised 9 males and 10 females, aged 2 to 21 years (median 8 years). All patients were ethnically Chinese. The clinicopathological findings of our cases are summarized in Table 1.

The main clinical features were papules (n = 19/19, 100%), and fever (n = 18/19, 94.7%). Only one patient (case 8) had no B symptom at the diagnosis. All lesions were located in the skin, and they included papulovesicles, blisters, ulceration, and scars. Eruptions were seasonal; they typically occurred in spring or summer. Eighteen patients had recurrent and slowly progressive, relapsing clinical courses. One patient (case 19) presented with a severe HV. In the early stage, most skin lesions initially occurred after sun exposure and subsided after sun protection. The lesions typically appeared on the face and extremities. The skin lesions typically healed within 1–2 weeks, with vacciniform scarring, and they recurred in the same distribution. Rarely, cases presented with fever at the beginning. As the disease progressed, 15 patients (88%) presented with severe systemic manifestations, including intermittent fever, wasting, lymphadenopathy, and hepatosplenomegaly. Severe skin lesions presented as deep ulcers, necrosis, plaques, or face edema in these patients (Fig. 1). The ulcerations took a longer time to heal, and they left scars.

Six cases had a history of mosquito-bite hypersensitivity. Among these, four had a CD4+ phenotype, and the other two had a CD8+ phenotype. No patient was hypersensitive to light.

The available routine laboratory tests revealed that all patients (11/11) had elevated lactate dehydrogenase (LDH) levels (range 312 to 1202 IU/L), when they were initially diagnosed with HV-LPD. Available data for seven patients showed positive EBV DNA blood loads in all patients (n = 7/7). In the 9 patients who had the treatment record in Sun Yat-sen University Cancer Center, the range of time-to progression were from 0.2 to 7 years (median, 0.63 yrs). Both the LDH and EBV DNA values at disease progression or the last follow-up were shown in Table 2. Both of the LDH and EBV DNA values, the important index for lymphoma, reflected the effect of the treatment. During the treatments, both of the LDH and EBV DNA loads declined. However, both of the LDH and DNA loads rose to high levels when the disease progressed (Table 2).

**Histopathology**

Histologically, all the biopsies featured infiltration of atypical lymphoid cells surrounding blood vessels and skin appendages in the dermis. In 12 cases (63%), atypical lymphocytes had infiltrated deep into fatty tissue or subcutaneous tissue. They were small to intermediate in size, and they had enlarged, irregular nuclei with nucleoli, admixed with an inflammatory background composed of small lymphocytes, plasma cells, histiocytes, and eosinophils (Fig. 2). Interestingly, nine cases developed into systemic lymphoma; these displayed dense and diffuse, atypical, medium- or large-sized lymphocytes (Fig. 3). Mitoses were brisk. Tumor necrosis was observed. However, we observed no angio-invasion or vascular destruction in any of the nine cases analyzed.

Seven patients had lymph node biopsies. Four biopsies showed preserved architecture with open sinuses and
| Case | Age(y)/ Sex/ History (y) | Skin lesions/location | Systemic manifestations | Size of atypical cells/ infiltration depth/necrosis | LN, BM biopsy | LDH (IU/L) | Phenotype | Therapy | Best response to treatment | Current status | Survival after Diagnosis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 9/F/1 | PUCS/face, scalp, extremities | FHSL | Medium/dermis | EBV+ cells in interfollicular area of LN | 324 | CD8 | Chemotherapy (IMR) and Radiotherapy. Maintained herbal remedy | CR | AWD | 8.7Y |
| 2 | 13/F/3 | Erythema, PUCS/face, extremities, and areas not exposed to sun | FHSL | Medium/dermis and fatty tissue/Fatty tissue necrosis | EBV+ cells diffusely infiltrated LN | 624 | CD56 | Chemotherapy (NHL-BFM-90) for 3 cycles [14] | PD | DOD | 1.1Y |
| 3 | 8/M/1 | PUCS, nodules/face, extremities | FHSL | Medium/dermis | EBV+ cells present in interfollicular area of LN | 450 | CD56 | Chemotherapy (MTX + VP-16) and Radiotherapy | PR | AWD | 7.6Y |
| 4 | 4/M/1 | PUCS/ areas exposed to sun; HMB | Fever | Small and medium/dermis and subcutaneous tissue | ND | NA | CD4 | Herbal remedy | PD | AWD | 6Y |
| 5 | 5/M/1 | PUCS, nodules/face, extremities | FHS | Small and medium/dermis | ND | NA | CD8 | Chemotherapy (IMR) and Radiotherapy. Maintained Herbal remedy | PD | DOD | 4.4Y |
| 6 | 8/F/1.5 | PUCS/face, arms, areas not exposed to sun | FHSL | Medium and large/dermis | ND | NA | CD56 | NA | NA | DOD | 3Y |
| 7 | 10/M/3 | PUCS/face, extremities; HMB | FL | Small and medium/dermis and subcutaneous tissue | ND | 298.4 | CD8 | Chemotherapy (NHL-BFM-95) for 6 cycles [15] | PR | DOD | 2.2Y |
| 8 | 2/F/0.5 | PUCS, nodules/face, extremities | None | Medium/dermis and subcutaneous tissue | ND | NA | CD56 | NA | NA | LFU | LFU |
| 9 | 21/M/14 | PUCS/areas exposed and unexposed to sun; HMB | FSH, LP, nodules, HPS | Medium and large/dermis and subcutaneous tissue | EBV+ cells diffusely infiltrated LN and BM | 1202 | CD4 | Chemotherapy (GEM+VP+MTX+P-ASP+thalidomide for 6 cycles) | PR | DOD | 0.6Y |
| 10 | 7/F/1 | PUCS/face, extremities, trunk | Fever | Medium/dermis and fatty tissue | ND | NA | CD8 | NA | NA | LFU | LFU |
| 11 | 5/M/2 | PUCS, nodules/face, extremities, trunk; HMB | FHS | Medium/dermis | EBV+ cells in interfollicular area of LN | 318 | CD4 | Chemotherapy (NHL-BFM-95) for 6 cycles; Sibling HSCT; and EBV-CTL treatment [15] | CR | Alive without disease | 4.4Y |
| 12 | 13/F/1 | PUCS/face, extremities, trunk, and oral cavity | FL | Medium/dermis | BM- | 482 | CD56 | Chemotherapy (P-ASP+GEM+L-OHP) Maintained herbal remedy | PD | DOD | 2.2Y |
| 13 | 12/F/2 | PUCS, nodules/face, trunk, and extremities | FHS | Medium/dermis and fatty tissue | EBV+ cells diffusely infiltrated LN and BM | 3589 | CD56 | Chemotherapy (GEM for 6 cycles) and antivirus treatment (Ganciclovir) | CR | AWD | 3.2Y |
| 14 | 5/M/3 | PUCS/face, extremities, trunk | FL | Medium/dermis and subcutaneous tissue | BM- | 3346 | CD4 | Chemotherapy (First Line: GEM for 6 cycles, Second Line: VP-16 + VCR for 1 cycle, Third Line: VLB + PDN for 1 cycle) | PR | AWD | 2.9Y |
| Case | Age(y)/ Sex/ History(y) | Skin lesions/location | Systemic manifestations | Size of atypical cells/ infiltration depth/necrosis | LN, BM biopsy | LDH (IU/L) | Phenotype | Therapy | Best response to treatment | Current status | Survival after Diagnosis |
|------|-------------------------|-----------------------|------------------------|--------------------------------------------------|----------------|-----------|-----------|---------|----------------------------|---------------|--------------------------|
| 15   | 7/F/4                   | PUCS, face, extremities | FL                     | Medium/dermis                                    | BM-            | 323.2     | CD56      | Chemotherapy (GEM for 6 cycles) | CR             | DOD 1.3Y                |
| 16   | 12/F/4                  | PUCS, face, trunk, arms and legs, HMB | FHSL                  | Medium/dermis and fatty tissue                    | BM-            | NA        | CD4       | NA      | NA                        | DOD 0.7Y       |                          |
| 17   | 11/M/9                  | PUCS, nodules, face, arms, legs, and areas not exposed to sun, HMB | FHSL                  | Medium/dermis and subcutaneous tissue            | EBV+ cells diffusely infiltrated LN and BM              | 585        | CD4       | Chemotherapy (First Line NHL-BFM-95, Second Line GEM for 2 cycles) [15] | PD             | DOD 2.4Y                |
| 18   | 8/M/2                   | PUCS, face, arms, legs, and trunk | Fever                  | Medium/dermis and subcutaneous tissue            | BM-            | 312       | CD4       | Chemotherapy (methylprednisolone, azithromycin, acitretin, and cyclosporine) | PR             | AWD 2.2Y                |
| 19   | F/5/3                   | PUCS, face, legs, and trunk | Fever                  | Medium/dermis and subcutaneous tissue            | ND             | NA        | CD8       | NA      | NA                        | LFU           | LFU                      |

PUCS papulovesicles, ulcers, crust, scars, HMB Hypersensitivity to mosquito bites, FHSL fever, hepatosplenomegaly, lymphadnopathy, FHS fever, hepatosplenomegaly, FL fever, lymphadnopathy, NP nodules nasopharynx nodules, HPS hemophagocytic syndrome, LN lymph node, BM bone marrow, BM-BM not involved, AWD Alive with disease, DOD dead of disease, NA not applicable, ND not done, LFU lost to follow-up, IMR interferon, mechlorethamine, and retinoic acid, NHL Non Hodgkin lymphoma, BFM Berlin-Frankfurt-Münster, MTX methotrexate, VP-16 etoposide, P-ASP pegaspargase, HSCT hematopoietic stem cell transplantation, GEM gemcitabine, L-OHP oxaliplatin, VCR vincristine, VLB vinblastine, PDN prednisone, CR complete remission, PD progressive disease, PR partial remission
paracortical hyperplasia. Cells that had infiltrated the lymph node were small- and medium-sized, with irregular nuclei and inconspicuous nucleoli. Cases 2, 9, and 17 progressed to systemic NK/T cell lymphoma. They exhibited diffuse effacement of the normal nodal architecture, due to the infiltration of homogeneous medium and large mixed lymphocytes with hyperchromatic nuclei and irregular nuclear contours. Cases 9, 13, and 17 harbored bone marrow that had been infiltrated by atypical lymphocytes.

**Immunohistochemical studies and EBERs**

The immunohistochemical findings are summarized in Table 3. The lymphoid cells that had infiltrated under the epidermis were 100% positive for CD3 and TIA1, and partially expressed CD30. With in situ hybridization, all cases displayed the presence of EBERs. Cells that carried EBERs were concentrated mainly around blood vessels and adnexa in the dermis (Figs. 2 and 3), but also in subcutaneous tissue.

Of 19 patients, five biopsies (26%) had CD8+ T cells, but no CD4+ or CD56+ cells (Fig. 2c). Seven (37%) had initial biopsies with CD4+ T cells, but no CD8+ T cells or CD56+ cells (Fig. 3c). Seven biopsies (37%) had CD56+ cells, but no CD4+ or CD8+ T cells, which indicated an NK-cell phenotype.

**Molecular studies**

Molecular analyses demonstrated that 7 of the 12 biopsies with a T-cell phenotype had undergone monoclonal rearrangements in the TCR genes. These seven cases were originally classified as HVLL, based on the monoclonality of the TCR gene rearrangements and fulfillment of the 2008 WHO classification criteria. The three biopsies with an NK-cell phenotype lacked detectable clonal rearrangement.

**Treatment and outcome**

Due to the long clinical course, the patients received a variety of treatments. Most patients were primarily treated with immunomodulating or immunosuppressive therapies, such as steroid cream or interferon, mechlor-ethamine, retinoic acid, etc. In the early stage, skin lesions typically improved with these treatments, but later, these treatments lost some efficacy.

Among the 19 patients, nine (47.4%) received chemotherapy, one patient (5.3%) received an herbal remedy, one patient (5.3%) received a combination of chemotherapy and radiotherapy, one patient (5.3%) received a combination of chemotherapy and herbal remedy, and two patients (10.5%) received sequential chemotherapy, radiotherapy, and herbal remedy. The other five patients (26.3%) received no anti-tumor treatment. The main

| Case | EBV DNA (copy/ml) | LDH (IU/L) | Time-to-progression | Current status |
|------|------------------|------------|---------------------|---------------|
|      | Before treatment | The minimum level during treatment | Progression/last follow-up | Before treatment | The minimum level during treatment | Progression/last follow-up |              |               |
| Case 1 | ND | ND | ND | 324 | ND | 207.7 | 7.0y | AWD |
| Case 2 | ND | ND | ND | 624 | 215 | 315.7 | 0.2y | DOD |
| Case 7 | 1.88 × 10^8 | 6.63 × 10^5 | 1.33 × 10^6 | 298.4 | 206.2 | 888 | 0.8y | DOD |
| Case 9 | 5.62 × 10^6 | 2.0 × 10^1 | 6.83 × 10^4 | 1202 | 248.7 | 1166 | 2.1y | AWD |
| Case 11 | 5.68 × 10^6 | 6.93 × 10^4 | 5.95 × 10^4 | 318 | 179.6 | 259.8 | NA | Alive without disease |
| Case 13 | 1.70 × 10^5 | 6.0 × 10^4 | 2.69 × 10^3 | 358.9 | 238.6 | 248.9 | 2.1y | AWD |
| Case 14 | 3.95 × 10^5 | 6.59 × 10^3 | 4.53 × 10^4 | 334.6 | 203.7 | 276.3 | 0.3y | AWD |
| Case 15 | 6.94 × 10^5 | 1.20 × 10^1 | 7.56 × 10^4 | 323.2 | 251.7 | 624.4 | 0.75y | DOD |
| Case 17 | 1.58 × 10^5 | 2.25 × 10^4 | 3.09 × 10^3 | 585 | 119.4 | 363.9 | 0.25y | DOD |

AWD Alive with disease, DOD dead of disease, NA not applicable, ND not done
Chemotherapy regimens in our study were BFM-90/95, for children with non-Hodgkin lymphoma (NHL), and gemcitabine for adults with extranodal NK/T-cell lymphoma, nasal type. Only one patient (case 11) in our study received an allogeneic hematopoietic stem cell transplantation and EBV-specific cytotoxic T lymphocyte (EBV-CTL) treatment after chemotherapy.

Among the 14 patients that received treatment, four patients (28.6%) achieved complete remission (CR), five patients (35.7%) achieved partial remission (PR), and five patients (35.7%) had progressive disease. Among the latter, four patients developed systemic lymphoma and died of disease during the anti-tumor treatment. Three patients died of disease during the follow-up with the best effect of CR or PR. The 2-year, 3-year and 5-year OS was 78.6, 56.3 and 45.0%, respectively.

Among all of the 19 patients in our study, the 2-year, 3-year and 5-year OS were 75.0, 47.6 and 38.1%, respectively, excluding 3 patients who lost to the follow up. Nine patients developed systemic lymphoma and died of disease with or without treatment.

**Differences between patients with T-cell and NK-cell phenotypes**

We compared the clinical features between patients with T-cell and NK-cell phenotypes. The male-to-female ratios were quite different (T cell: 2:1 vs. NK cell: 1:6), showing female dominance in NK phenotype. But the median ages were similar between groups (7.5 vs. 8 years). The two groups had similar skin lesions, and both had systemic symptoms at presentation. HMB was documented only for the T-cell phenotype, including five patients with a CD4+ T-cell phenotype and one patient with a CD8+ T-cell phenotype. Progression to T/NK-cell lymphoma in the nasal region occurred in one patient (case 9) with a CD4+ T-cell phenotype. The two groups had similar incidences of systemic lymphoma, and the clinical outcomes were similar in all patients with T-cell lineage disease (CD4+ and CD8+) and those with NK-cell lineage disease ($p = 0.578$ for T-cell vs. NK-cell, Fig. 4).

**Discussion**

HV-LPD is extremely rare in Western countries. Most studies described recurrent skin lesions with T-cell or NK-cell phenotypes in children and adolescents from Asian and Latin American countries [11, 16, 17]. South China has a high-incidence of EBV-associated nasopharyngeal carcinoma and extranodal NK/T-cell lymphoma, nasal type [13]. In our previous study, HV-LPD comprised 8.1% of peripheral T/NK-cell neoplasms in children and adolescents [18], indicating the prevalence of specific EBV strains and genetic background or genetic predisposition, a hypothesis that requires further study for confirmation.

In our study, all cases of HV-LPD had undergone an initial smoldering stage that lasted from 1 to 10 years. The early stage clinical features fit the criteria for hydroa vacciniforme. All patients had self-limited vesiculopapular eruptions on exposed areas, including the face, dorsal surfaces of the hands, and lower limbs, with no manifestation or only mild fever. As the disease progressed,
most patients exhibited severe, extensive skin lesions with systemic manifestations, including fever, hepatosplenomegaly, and lymphadenopathy, consistent with other reports [2, 19, 20]. The term HV-LPD changed from hydroa vacciniforme-like lymphoma to lymphoproliferative disorder by the 4th revised edition of WHO classifications would be a more appropriate classification and a more descriptive term [1, 21, 22].

The histopathology of biopsies from 11 patients showed that atypical lymphocytes had infiltrated, and subcutaneous tissues were involved. Nine patients died of systemic T/NK lymphoma. All had elevated LDH levels (range: 318 to 1202 IU/L) and higher EBV DNA blood loads. Our study confirmed previous results that indicated that HV-LPD and HVLL groups comprised a spectrum of cutaneous CAEBV forms. HV-LPD is an EBV-associated lymphoproliferative disorder of T or NK-cell phenotype with risk for progression to HVLL.

There is no method in the literature for distinguishing between HV-LPD and progression to systemic NK/T cell lymphoma. This lack of distinction often confuses pathologists and chemotherapy physicians. The challenge remains to identify morphological or clinical markers for predicting which patients are at high risk of progressing to systemic lymphoma. We found that the presence of a TCR gene rearrangement was not useful for making a diagnosis of lymphoma, because, in our study, case 14 and 18 had monoclonalities in the early stage. Four patients developed systemic lymphoma and died of the disease progression during chemotherapy treatment. As shown in Table 1, all those patients displayed atypical, medium- to large-sized cells with deep skin ulcers, highly elevated LDH, long-lasting high EBV DNA loads (typically > 1 × 10^5 copies), severe systemic manifestations, diffuse effacement of normal nodal architecture by atypical cell infiltration, and bone marrow involvement. Older patients tended to develop lymphoma, which was probably associated with an irreversible process [23].

HV-LPD was originally thought to be derived from skin-homing cytotoxic T-cells or NK cells. The majority of

Fig. 3 Morphology and immunophenotype of case 9, which progressed to systemic T-cell lymphoma. a Skin biopsy shows a diffuse, atypical lymphocyte infiltrate, with a marked epidermis and subcutaneous distribution (hematoxylin and eosin stain [H&E], 40x). b Skin biopsy shows medium- to large-sized lymphocytes, with enlarged, oval and pleomorphic nuclei (H&E, 200x). c Strong staining of CD4+ cells (IHC, 200x). d GranB Positive cells (IHC 100x). e Ki67 expression is high in 70% of tumor cells (IHC 100x). f In situ hybridization shows that neoplastic cells are positive for EBV-encoded RNA (100x)
Table 3 Immunophenotype and molecular analysis of biopsies from 19 patients with HV-LPD

| Case | CD3 | CD8 | CD4 | CD56 | TIA1 | CD30 | Ki67 | EBERs | TCR rearrangement |
|------|-----|-----|-----|------|------|------|------|-------|------------------|
| 1    | +   | +   | –   | –    | +    | –    | 30%  | +     | –                |
| 2    | +   | –   | –   | +    | +    | –    | 60%  | +     | –                |
| 3    | +   | –   | –   | +    | +    | –    | 30%  | +     | ND               |
| 4    | +   | –   | +   | –    | +    | P+   | 80%  | +     | –                |
| 5    | +   | +   | –   | –    | +    | ND   | 30%  | +     | –                |
| 6    | +   | –   | –   | +    | ND   | 30%  | +     | ND    |
| 7    | +   | +   | –   | +    | –    | 30%  | +     | –                |
| 8    | +   | –   | –   | +    | +    | P+   | 50%  | +     | ND               |
| 9    | +   | –   | +   | –    | +    | P+   | 70%  | +     | +                |
| 10   | +   | +   | –   | –    | +    | ND   | 20%  | +     | +                |
| 11   | +   | +   | –   | –    | +    | –    | 30%  | +     | +                |
| 12   | +   | –   | –   | +    | +    | –    | 30%  | ND    |
| 13   | +   | –   | +   | –    | +    | +    | 70%  | ND    |
| 14   | +   | –   | +   | –    | +    | ND   | 40%  | +     | +                |
| 15   | +   | –   | –   | +    | +    | –    | 60%  | +     | –                |
| 16   | +   | –   | +   | –    | +    | P+   | 70%  | +     | +                |
| 17   | +   | –   | +   | –    | +    | +    | 40%  | +     | +                |
| 18   | +   | –   | +   | –    | +    | –    | 10%  | +     | +                |
| 19   | +   | –   | +   | –    | +    | –    | 60%  | +     | –                |

EBERs: EBV-encoded RNAs, TCR: T-cell receptor, P: partial, ND: not done, F: failure to extract sample DNA

Fig. 4 Kaplan-Meier survival curves for patients with HV-LPD, categorized by a clinicopathological feature. Patients with T-cell lineage disease (CD4 and CD8) had similar clinical outcomes with those of NK-cell lineage disease for all the patients with or without the treatment (n = 19, p = 0.578 for T-cell vs. NK-cell). Survival-time differences were analyzed with the log-rank test.
studies on HV-LPD reported a T-cell phenotype with divergent immunophenotype of either CD4 or CD8 [24, 25]. However, EBV-infected cells might be CD4+ T cells, CD8+ T cells, or NK cells. EBV-infected cellular lines have varied in different studies and populations. Doeden et al. described patients with a NK-cell phenotype [6]. Interestingly, our cases exhibited the CD4+ phenotype (7/19), the CD8+ phenotype (5/19), and the NK-cell phenotype (7/19). The clinical course of the CD56 phenotype was not more aggressive than that of the T-cell phenotype; only two cases died of systemic NK lymphoma. The other two patients with the CD56 phenotype had longer clinical courses, and were alive with disease after 3 or 7 years of follow up. This finding was consistent with findings in previous reports [5]. Doeden et al. described two boys with the CD56 phenotype that exhibited an indolent disease course. In the present study, T-cell or NK-cell lineages were not identified as independent adverse prognostic factors. However, the sample size was quite small; in future, a larger sample is needed to analyze the association between phenotype and disease course or outcome.

Currently, there is no standard therapy for patients with HV-LPD. Several treatments for HV-LPD have been suggested, including antiviral agents, anti-inflammatory agents, radiotherapy, chemotherapy, EBV-specific cytotoxic T-cell regimen, bone marrow or allogeneic hematopoietic stem cell transplantation, and immunomodulative therapies, such as interferon-a or interleukin-2 [5, 26–28]. Chemotherapy and/or immunomodulative therapies have been used to treat many patients in progressing stages, but they provided only temporary remission or limited benefit. In this study, the main regimens of chemotherapy were BFM-90/95, for pediatric non-Hodgkin lymphoma (NHL), and gemcitabine, for adult extranodal NK/T-cell lymphoma, nasal type. The effects were typically transient, and they did not result in persistent remission. These treatments killed the EBV-infected cells, but they could not prevent patients from EBV re-infection. Only one patient (No. 11) received allogeneic hematopoietic stem cell transplantation and EBV-CTL treatment after chemotherapy, and that patient was the only one alive without disease at the latest follow up. Thus, allogeneic HSCT appeared to be the only curative treatment for HV-LPD. This result was consistent with those from previous reports [29, 30]. In summary, we demonstrated that HVL-LPD had specific features that could be classified into different clinicopathological categories; this finding might potentially impact future clinical trials and outcomes. We established the diagnosis of systemic EBV+ T/NK cell lymphoma as a result of HV-LPD progression, based on the clinical, histopathological, and immunohistochemical features, in addition to EBV detection. We showed that EBV-DNA loads, LDH, cytopenia, and multiorgan destructive involvement were poor independent prognostic factors, distinct from findings in previous studies. The monoclonality of TCR gene rearrangements could be a referential index for evaluating HV-LPD progression. Future studies on genetic abnormalities might contribute to our understanding of the biological behavior of HVL-LPD and to establishing a therapeutic strategy for patients.

**Abbreviations**

CAEBV: Chronic active EBV; EBV: Epstein-Barr virus; EBV-CTL: EBV-specific cytotoxic T lymphocyte; HVLL: Hydroa vacciniforme-like lymphoma; HV-LPD: Hydroa vacciniforme-like lymphoproliferative disorder; NHL-BFM-90/95: The Berlin-Frankfurt-Munster Group Trial NHL-BFM 90/95 regimen for the treatment of the children and adolescents with Non-Hodgkin’s lymphomas; OS: Overall survival; PFS: Progression-free survival

**Acknowledgements**

We thank Ruoyao Zhou for editing the manuscript.

**Authors’ contributions**

GN and CYQ contributed equally to the work. GN and CYN designed the study, and GN drafted the manuscript. RHL and HYH contributed to the diagnoses. WY analyzed the clinical data. LM and FYF assisted in patient selection and figure preparation. RHL guided the whole study and revised the manuscript. All authors read and approved the final manuscript.

**Funding**

This study was supported by the Sister Institution Network Fund of the University of Texas MD Anderson Cancer Center (awarded to Huilan Rao), the Natural Science Foundation of Guangdong Province (No. 2018A030313663), and the Medical Science and Technology Program of Guangdong Province, China (A 2018001).

**Availability of data and materials**

The datasets generated and/or analyzed in this study are available from the corresponding author upon reasonable request.

**Ethics approval and consent to participate**

The study was approved by the Ethics Committee of Sun Yat-Sen University Cancer Center (approval no. B2018–129-01). This study was granted exemption from requiring informed consent from participants. All experiments were carried out in accordance with relevant guidelines and regulations. The raw data of this study were deposited in the Research Data Deposit public platform (www.researchdata.org.cn), with the approval RDD number as RDDA2019000984.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, People’s Republic of China.
2. Department of Pathology, Sun Yat-sen University Cancer Center, No. 651, Dongfeng Road East, Guangzhou, Guangdong 510060, People’s Republic of China.
3. Hematoxylin Morphology Chamber, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, People’s Republic of China.
4. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, People’s Republic of China.

**Received:** 25 April 2019 **Accepted:** 9 July 2019

**References**

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (IARC WHO classification of tumours) revised 4th edition. Lyon: IARC Press; 2017.
